Share This Page
Drug Price Trends for ANAGRELIDE HCL
✉ Email this page to a colleague
Average Pharmacy Cost for ANAGRELIDE HCL
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| ANAGRELIDE HCL 1 MG CAPSULE | 00172-5240-60 | 1.48501 | EACH | 2025-06-18 |
| ANAGRELIDE HCL 1 MG CAPSULE | 62135-0313-60 | 1.48501 | EACH | 2025-06-18 |
| ANAGRELIDE HCL 0.5 MG CAPSULE | 00172-5241-60 | 0.71957 | EACH | 2025-06-18 |
| ANAGRELIDE HCL 1 MG CAPSULE | 13668-0462-01 | 1.48501 | EACH | 2025-06-18 |
| ANAGRELIDE HCL 0.5 MG CAPSULE | 13668-0453-01 | 0.71957 | EACH | 2025-06-18 |
| ANAGRELIDE HCL 0.5 MG CAPSULE | 62135-0312-12 | 0.71957 | EACH | 2025-06-18 |
| ANAGRELIDE HCL 1 MG CAPSULE | 00172-5240-60 | 1.49528 | EACH | 2025-05-21 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for Anagrelide Hydrochloride
Introduction to Anagrelide Hydrochloride
Anagrelide hydrochloride, commonly known by the brand name Agrylin or Xagrid, is an oral imidazoquinazoline used primarily for the reduction of thrombocytosis in patients with high-risk essential thrombocythemia (ET) and other myeloproliferative neoplasms. Here, we will delve into the market analysis and price projections for this drug.
Market Size and Growth
The anagrelide hydrochloride market has experienced significant growth in recent years. Here are some key points regarding its market size and growth:
- Current Market Size: The anagrelide hydrochloride capsule market is expected to grow at a CAGR of 3 to 5% from its current valuation. Although the exact current market size in terms of USD is not specified, the growth rate indicates a robust expansion[2].
- Forecast Period: The market is forecasted to continue its growth from 2023 to 2031. This period is crucial for understanding the long-term trends and opportunities in the market[2].
Market Segmentation
The market for anagrelide hydrochloride is segmented based on several factors:
- Application: The drug is used in various settings such as hospitals, clinics, and recovery centers. This segmentation helps in understanding the demand from different healthcare sectors[2].
- Product: Anagrelide hydrochloride is available in different dosages, primarily 0.5 mg and 1 mg capsules. This segmentation is important for pricing and market strategy[2].
- Geography: The market is segmented geographically into North America, Europe, Asia-Pacific, South America, and the Middle East & Africa. The Asia-Pacific region, particularly countries like India, is a significant market due to growing healthcare needs and increasing access to medications[2].
Key Players
The anagrelide hydrochloride market is dominated by several key players:
- Takeda: Known for its extensive portfolio of pharmaceuticals, Takeda is a major player in the anagrelide hydrochloride market.
- Teva: A global leader in generic and specialty medicines, Teva also plays a significant role.
- Torrent: An Indian pharmaceutical company with a strong presence in the global market.
- Mylan: Now part of Viatris, Mylan is another major player in the generic and specialty pharmaceuticals market.
- Sandoz: A division of Novartis, Sandoz is a leading generic pharmaceutical company[2].
Market Dynamics
Drivers
- Increasing Demand: The growing incidence of myeloproliferative neoplasms and the need for effective treatments drive the demand for anagrelide hydrochloride.
- Approval and Licensing: The drug's approval in various regions, including Europe, the USA, and Japan, has expanded its market reach[3].
Restraints
- Side Effects: Anagrelide hydrochloride is associated with several side effects, including cardiovascular issues, which can limit its use in certain patient populations[5].
- Alternative Treatments: The presence of alternative treatments like hydroxycarbamide (HC) and interferon alpha (IFN α) can compete with anagrelide hydrochloride in the market[3].
Opportunities
- Emerging Markets: Growing healthcare infrastructure and increasing access to medications in emerging markets, particularly in Asia-Pacific, offer significant opportunities for growth.
- Research and Development: Ongoing research into new indications and improved formulations could expand the market further[2].
Price Projections
The pricing of anagrelide hydrochloride can be influenced by several factors, including production costs, regulatory environments, and market competition.
- Current Pricing: The exact current pricing of anagrelide hydrochloride capsules varies by region and supplier. However, it is generally priced in the range of specialty pharmaceuticals.
- Future Pricing Trends: Given the expected growth rate of 3 to 5%, prices may stabilize or increase slightly as demand rises and production costs are managed. However, intense competition from generic versions could keep prices in check[2].
Import and Export Trends
The global import and export data provide insights into the market's supply chain and demand:
- Importers: The United States, India, and South Korea are the top importers of anagrelide hydrochloride, indicating strong demand in these regions[4].
- Exporters: India, the United States, and Germany are the primary exporters, highlighting their significant role in the global supply chain[4].
Clinical Use and Efficacy
Anagrelide hydrochloride is highly effective in reducing platelet counts, with response rates ranging between 76% and 94% in clinical studies. It is particularly useful as a second-line treatment for patients who are refractory or intolerant to first-line treatments like hydroxycarbamide[3].
Regulatory Considerations
The drug is approved in various regions with specific indications:
- Europe: Approved as a second-line agent for reducing thrombocytosis in high-risk ET.
- USA and Japan: Licensed for use in any myeloproliferative neoplasm-associated thrombocytosis and for the amelioration of thrombo-hemorrhagic events[3].
Conclusion
The anagrelide hydrochloride market is poised for significant growth driven by increasing demand, expanding approvals, and emerging market opportunities. However, it faces challenges from side effects and alternative treatments. Understanding these dynamics is crucial for market players to navigate and capitalize on the growing demand for this drug.
Key Takeaways
- Market Growth: Expected to grow at a CAGR of 3 to 5% from 2023 to 2031.
- Key Players: Takeda, Teva, Torrent, Mylan, and Sandoz are major players.
- Market Segmentation: Segmented by application, product dosage, and geography.
- Clinical Efficacy: Highly effective in reducing platelet counts with response rates between 76% and 94%.
- Regulatory Environment: Approved in Europe, the USA, and Japan with specific indications.
FAQs
Q: What is the primary use of anagrelide hydrochloride? A: Anagrelide hydrochloride is primarily used for the reduction of thrombocytosis in patients with high-risk essential thrombocythemia (ET) and other myeloproliferative neoplasms.
Q: Which regions are the top importers of anagrelide hydrochloride? A: The United States, India, and South Korea are the top importers of anagrelide hydrochloride.
Q: What are the common side effects of anagrelide hydrochloride? A: Common side effects include cardiovascular issues such as congestive heart failure, myocardial infarction, and cardiomyopathy.
Q: Who are the major players in the anagrelide hydrochloride market? A: Major players include Takeda, Teva, Torrent, Mylan, and Sandoz.
Q: What is the expected growth rate of the anagrelide hydrochloride market? A: The market is expected to grow at a CAGR of 3 to 5% from 2023 to 2031.
Sources
- Market Research Intellect - Anagrelide Hydrochloride Capsule Market Size And Forecast[2].
- Dovepress - Spotlight on anagrelide hydrochloride for the treatment of essential thrombocythemia[3].
- Volza - Anagrelide Imports in World[4].
- FDA - Agrylin® Capsules[5].
More… ↓
